Abstract

6-Hydroxy-D-nicotine oxidase, an enzyme with FAD covalently attached to the protein, contains 6 cysteine residues in positions 45 (Cys1), 59 (Cys2), 136 (Cys3), 173 (Cys4), 260 (Cys5) and 433 (Cys6). Cys2, 3, 5, and 6 were replaced with serine by site-directed mutagenesis. The effects of these exchanges on enzyme activity, the autocatalytic incorporation of the cofactor, and the interaction of the mutant proteins with molecular chaperones were analyzed. The flavinylation of 6-hydroxy-D-nicotine oxidase is dependent on the presence of allosteric effectors, e.g. glycerol 3-phosphate or other phosphorylated tricarbon compounds. Replacement of Cys2 or Cys5 abolished this dependence. Covalent incorporation of FAD was reduced to an undetectable level in the Cys3 and Cys5 mutants. Replacement of Cys6 by Ser had no significant effect on enzyme activity and cofactor attachment. Deletion of two amino acids, Phe and Arg, situated 12 and 11 amino acid residues, respectively, from the carboxyl terminus of the protein, resulted in an inactive enzyme with no covalently bound FAD. This result indicates that almost the entire protein chain has to be synthesized before the cofactor can be incorporated, making a cotranslational flavinylation step rather unlikely. The distribution of the 6-hydroxy-D-nicotine oxidase polypeptide between the high molecular weight complexes and the free soluble form was analyzed by gel filtration on Sephacryl S-200. The wild-type holoenzyme as well as the wild-type apoenzyme were recovered in the eluent fraction of the column while the mutant proteins were retained in high molecular weight complexes, predominantly in those associated with GroEL, as revealed by immunoprecipitation. The extent of complex formation with this molecular chaperone depended on the position of the mutated Cys residue within the protein. Complex formation was highest with protein from the mutants Cys2 and Cys3, less with the Cys5, and absent with the Cys6 mutant protein. Thus, alterations in the amino-terminal part of the 6-hydroxy-D-nicotine oxidase appear more important for the interaction with molecular chaperones than alterations situated in the carboxyl-terminal part of the protein.

Highlights

  • 6-Hydroxy-D-nicotineoxidase, an enzyme with FAD 6-Hydroxy-~-nicotinoexidase belongs to a class of flavoencovalently attached to the protein, contain6s cysteine zymes with the cofactor covalently bound to the polypeptide residues in positions 45 (Cysl), 59 (Cysa), 136 (Cys3), chain by a histidyl-N3-8a-riboflavin linkage (for a recent 173(Cys4),260 (Cys5)and 433(Cys6)

  • The wild-type holoenzyme as well as thewild-type apoenzyme were recovered in the eluent fraction of the column while the mutant proteins were retained in high molecular weight complexes, predominantly in those associated with GroEL, as revealed by immunoprecipitation

  • Dithionitrobenzoic acid that interacts with free sulfhydryl groups inhibits both the covalent incorporation of FAD intothe 6-HDNO polypeptide and6-HDNOactivity [2]

Read more

Summary

MATERIALS ANDMETHODS

Bacterial Strains, Plnsmids, and Growth Conditions-As a host for plasmid pLM1702 carrying the 6-HDNO gene under the control of the tac promoter [18], the E. coli strain JM109 [7] was used. Following electrophoresis the gel was treated with Amplify (Amersham, Braunendonuclease BglII underlined and thereplaced nucleotide indicated schweig,Germany), dried, and exposedto Fuji X-Omat film (Siemens, by a dot; for the exchange of Cys by Ser as 5’-PCR primer and Freiburg, Germany) GCATGCATCCTAAGGTCGGGTTCTCTGGACTAG-3’, with the Gel Filtration of Cell Extracts on Sephacryl S-200 Columns-Exrecognition sequence for the endonuclease SphI underlined and the tract (100p l ) obtained from E. coli cells expressing plasmid pLM1702 replaced nucleotide indicated by a dot; as 3’-PCR primer the 23-mer with various mutant 6-HDNO polypeptides was applied to a 17 cm X oligonucleotide derived from the antisense DNA strand, 5’-GTTCA 1-cm Sephacryl S-200 column (Pharmacia, Freiburg, Germany).

RESULTS
Western performed with amounts Of
DISCUSSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.